Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of Collaboration for COVID-19 Vaccine

0

SAN DIEGO – (COMMERCIAL THREAD) – Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA drug company focused on infectious disease vaccine development and significant opportunity in the field of rare liver and respiratory diseases, today announced that Arcturus President and CEO Joseph Payne has met with Vietnam President Nguyen Xuan Phuc and Vingroup CEO Nguyen Viet Quang in New York to discuss the recently announced ongoing collaboration between Arcturus and Vingroup related to the supply of manufacturing COVID-19 vaccines. The Vietnamese delegation present at the meeting included prominent government officials including: President Nguyen Xuan Phuc, Deputy Minister of Health Tran Van Thuan, Minister of Planning and Investment Nguyen Chi Dung, Minister of Industry and Commerce Nguyen Hong Dien, Ambassador Ha Kim Ngoc, Chairman of the Cabinet of President Le Khanh Hai, and Minister of Construction Nguyen Thanh Nghi.

“We are really excited about the ongoing discussions to expand our collaboration with Vingroup, and we look forward to playing a significant role in supporting Vietnam’s response efforts to vaccinate its population against COVID-19,” said Joseph Payne, Chairman and Chief Executive Officer of Arcturus. “It was an honor to meet with President Nguyen Xuan Phuc and the delegation to discuss Vietnam’s progressive public health strategy. Vietnam should be recognized for its thoughtful planning and aggressive actions to tackle this pandemic, including its proactive approach to ensuring rapid access to vaccines targeting the worrisome variants of SARS-CoV-2. We look forward to a long and very productive collaboration.

About Arcturus Therapeutics

Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA drug and vaccine company with enabling technologies: (i) LUNAR® lipid-mediated delivery , (ii) STARR ™ mRNA technology and (iii) mRNA drug substance as well as expertise in manufacturing pharmaceuticals. Arcturus’ diverse portfolio of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, as well as other programs to potentially treat ornithine transcarbamylase deficiency (OTC) and cystic fibrosis, as well as partner programs such as Glycogen. Type 3 storage disease, hepatitis B virus and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapy platforms can be applied to many types of nucleic acid drugs including messenger RNA, small interfering RNAs, replicon RNA, antisense RNA, microRNA , DNA and gene editing therapies. Arcturus’ technologies are covered by its extensive patent portfolio (231 patents and patent applications, granted in the United States, Europe, Japan, China and other countries). Arcturus’ commitment to the development of new RNA-based therapies has led to collaborations with Janssen Pharmaceuticals, Inc., which is part of the pharmaceutical companies Janssen of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information, visit www.ArcturusRx.com. In addition, please contact us on Twitter and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for the safe harbor purposes of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included in this press release press, are forward-looking. statements, including those regarding strategy, future operations, collaborations, likelihood of success (including safety and effectiveness) of the Company’s pipeline, the Company’s efforts to develop a vaccine against COVID- 19 and its therapeutic potential based on the Company’s mRNA-based therapies, the likelihood that the Company will obtain authorization from regulatory authorities to conduct planned future clinical trials, the likelihood or timing of any regulatory approval, the status or expansion of any collaboration, the Company’s manufacturing plans or technologies, the Company’s efforts to support Vietnam and any other country in COVID-19 protection efforts, the likelihood that a patent is issued from a patent application, its current cash position and expected cash consumption and the impact of general business and economic conditions. Actual results and performance could differ materially from those projected in the forward-looking statements due to many factors, including, without limitation, the ability to enroll subjects in clinical trials due to the COVID pandemic. 19, the impact of the commercialization of third-party COVID-19 vaccines on the design and ability to conduct clinical trials, availability of manufacturing capacity and raw materials, unexpected clinical results, government regulations affecting the regulatory environment or intellectual property landscape, and general market conditions that may prevent such achievements or performance. Arcturus may not actually carry out plans, achieve intentions or meet expectations or projections disclosed in forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties, including those discussed under “Risk Factors” in Arcturus’ annual report on Form 10-K for the year ended. December 31, 2020, and in subsequent filings with, or submissions to, the SEC. Unless otherwise provided by law, Arcturus disclaims any intention or obligation to update or revise forward-looking statements, which are only valid on the date on which they were made, whether as a result of new information, future events or circumstances or otherwise.



Source link

Share.

Leave A Reply